RTW investing $75m in UroGen Pharma

RTW Investments has agreed to back uro-oncology specialist UroGen Pharma with $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of UroGen products.

Founded by Roderick Wong in 2011, New York-based RTW operates both a venture strategy and hedge fund strategy totaling a combined $3.6 billion. Wong, an MD, is responsible for managing the firm’s investments focused on innovative drug development. Prior to forming RTW, he was a managing director and sole portfolio manager for the Davidson Kempner Healthcare Funds.

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

Get started

Back to top button

Start Your Days in the Know

 

Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!